Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
ONCR-177 is an oncolytic herpes simplex virus (HSV) engineered to express PD-1 and CTLA-4 antagonists, IL-12, CCL4, and the extracellular domain of FLT3LG, and to contain a microRNA-binding cassette that potentially allows selective HSV replication in tumor cells, which may enhance anti-tumor immune response and induce tumor cell killing (Cancer Res 2019;79(13 Suppl):Abstract nr 1455).
|DrugClasses||CTLA4 Inhibitor 3|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|ONCR-177 + Pembrolizumab||ONCR-177 Pembrolizumab||0||1|